Crystalys Therapeutics
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $250.0Mattributed |
|---|---|
| Latest round | series-a, $205.0M, 2025-10-01attributed |
| Founded | 2023 |
| Headquarters | San Francisco CA |
| Industry | bio |
| Stage | series-a |
| Website | crystalys.com |
Crystalys Therapeutics develops dotinurad, a once-daily oral URAT1 inhibitor that lowers serum uric acid in gout patients by promoting urinary excretion. It treats US gout patients with inadequate response to first-line urate-lowering therapy. Dotinurad has already treated 1.2M+ patients in Japan since 2020 before its US Phase 3.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-01 | series-a | $205.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $205.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $250.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | crystalys.com, read 2026-05-02 |
| Description | self-reported | crystalys.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.